Several antibiotic drug developers are looking to alternative delivery systems to offer localized delivery for anti-infective agents – such as inhaled formulations that target the lungs – a pathway that could result in new approvals for older molecules.
Pulmonary delivery technology that could make new products from generic antibiotics has attracted a range of respiratory-focused companies to the anti-infective space. Bayer AG and Nektar Therapeutics, Aradigm Corp., Savara Inc
The State Of The Antibiotics Pipeline
The conclusion of Scrip's review of antibiotic drug development and the impact of incentives like the US FDA's Qualified Infectious Disease Product program.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
